Biotech Values

[DewDiligence]

Has fear of a hypoglycemic event—rather than hypoglycemic events per se—been previously used as an endpoint in a clinical study? It’s an endpoint in the phase-2 study of LY2605541 (jointly owned by LLY and B-I):

http://finance.yahoo.com/news/lilly-boehringer-ingelheim-present-health-101500746.html

Study results showed that in addition to clinical results showing a statistically significant 48 percent baseline adjusted reduction in nocturnal hypoglycaemia compared with insulin glargine [0.25 vs. 0.39 events/ 30 days/patient, after adjusting for baseline hypoglycaemia events (p=0.020)], patients treated with LY2605541 reported a statistically significant reduction in the anxiety and fear associated with experiencing a hypoglycaemic event based upon the Adult Low Blood Sugar Survey (ALBSS).

LY2605541 is yet another drug whose sponsors seek to chip away at the huge market for SNY’s Lantus.